Clinical Trial Update: PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating PD-1 knockout EBV-specific cytotoxic T lymphocytes for advanced EBV-associated malignancies, including gastric cancer, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Gastric Cancer
• Hodgkin Lymphoma
• Nasopharyngeal Carcinoma
• T-cell Lymphoma

Drugs mentioned

• PD-1 knockout EBV-CTLs

Snippet

Sponsor: Yang Yang | Conditions: Stage IV Gastric Carcinoma, Stage IV Nasopharyngeal Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN